These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11685728)

  • 1. Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer.
    Dreicer R; Klein EA
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):45-8. PubMed ID: 11685728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
    Oh WK; George DJ; Kaufman DS; Moss K; Smith MR; Richie JP; Kantoff PW
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):40-4. PubMed ID: 11685727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
    Hussain A; Dawson N; Amin P; Naslund M; Engstrom C; Chen T
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):22-31. PubMed ID: 11685725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
    Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
    Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
    Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
    Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
    Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
    Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA
    J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
    Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
    Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
    Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
    Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
    Febbo PG; Richie JP; George DJ; Loda M; Manola J; Shankar S; Barnes AS; Tempany C; Catalona W; Kantoff PW; Oh WK
    Clin Cancer Res; 2005 Jul; 11(14):5233-40. PubMed ID: 16033841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
    Logothetis CJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
    Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
    Dreicer R; Magi-Galluzzi C; Zhou M; Rothaermel J; Reuther A; Ulchaker J; Zippe C; Fergany A; Klein EA
    Urology; 2004 Jun; 63(6):1138-42. PubMed ID: 15183967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
    Nosov A; Reva S; Petrov S; Mamijev E; Novikov R; Veliev E; Imkamp F; Tolkach Y; Moiseenko V
    Prostate; 2016 Nov; 76(15):1345-52. PubMed ID: 26864707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
    Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
    Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
    Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
    J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
    Berry W; Dakhil S; Gregurich MA; Asmar L
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):8-15. PubMed ID: 11685723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.